How is the Attention Deficit Hyperactivity Disorder Market Poised for Growth: Trends and Opportunities Through 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the attention deficit hyperactivity disorder market size evolved in recent years?
Recent years have seen robust expansion in the attention deficit hyperactivity disorder market. Predictions indicate a rise from $16.29 billion in 2024 to $17.43 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this uptick during the historical period include the escalating incidence of ADHD, heightened awareness of the condition, ever-increasing healthcare spending, and government-led mental health awareness campaigns.
What are the predictions for the attention deficit hyperactivity disorder market size in the coming years?
Expectations are high for robust expansion within the attention deficit hyperactivity disorder market in the coming years. The market is predicted to burgeon to $22.59 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%. The surge during the projected period is due to factors such as an uptick in both child and adult patients undergoing treatment, a sophisticated healthcare infrastructure, an increased focus on personalized medicine, a more accepting attitude towards mental health disorders, and a rise in the use of additives and preservatives in children’s food. Noteworthy trends for the forecast period encompass technological enhancements and innovative therapies, progress in diagnostic and treatment strategies, the creation of fresh therapeutic agents, a move towards non-stimulant medication, and strides in pharmaceutical treatments.
Get your attention deficit hyperactivity disorder market report here!
What key factors are fueling the growth of the attention deficit hyperactivity disorder market?
The increase in the use of personalized medicine is likely to stimulate higher growth in the Attention Deficit Hyperactivity Disorder (ADHD) market. As an approach to healthcare, personalized medicine is pivotal as it customizes treatments based on individual genetic, environmental, and lifestyle factors, thereby delivering more accurate and efficacious health services. The integration of advances in genomic technologies has enhanced the practice of personalized medicine, particularly in developing therapies that are finely targeted and more effective since they are based on the individual’s genetic makeup. The ADHD facet contributes considerably to personalized medicine by enabling the development of tailor-made treatment strategies that take into account a patient’s distinctive genetic, environmental, and behavioral aspects, promoting a more targeted and efficient therapeutic response. An example of this was in February 2024 when a report issued by the Personalized Medicine Coalition (PMC), a non-profit organization in America, revealed that for the fourth year running, personalized medicines represented over one-third of new drug approvals by the FDA in 2023. The FDA approved 16 new personalized treatments for uncommon diseases (an increase from 6 in 2022), 7 cancer drugs, and 3 for other conditions. As a result, the ADHD market growth is being spurred by the continued uptake of personalized medicine.
How is the global attention deficit hyperactivity disorder market divided into key segments?
The attention deficit hyperactivity disorder market covered in this report is segmented –
1) By Type: Stimulants, Non-Stimulants
2) By Age Group: Children, Adults
3) By Gender: Male, Female
4) By Dosage Form: Tablets, Capsules, Other Dosage Forms
5) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
Subsegments:
1) By Stimulants: Methylphenidate-based Medications, Amphetamine-based Medications, Mixed Amphetamine Salts, Dexmethylphenidate
2) By Non-Stimulants: Atomoxetine (Strattera), Guanfacine (Intuniv), Clonidine (Kapvay), Bupropion (Wellbutrin)
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21108&type=smp
Who are the key firms paving the way for growth in the attention deficit hyperactivity disorder market?
Major companies operating in the attention deficit hyperactivity disorder market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Neos Therapeutics Inc., Collegium Pharmaceutical Inc., Mallinckrodt Pharmaceuticals plc, Tris Pharma Inc., Arbor Pharmaceuticals LLC, Akili Interactive Labs Inc., Mind Medicine (MindMed) Inc., NeuroSigma Inc., KemPharm Inc., RespireRx Pharmaceuticals Inc., Cingulate Therapeutics LLC, Adlon Therapeutics L.P.
Which trends are expected to transform the attention deficit hyperactivity disorder market?
Key players in the ADHD (attention deficit hyperactivity disorder) market are striving to develop creative pharmaceuticals like extended-release tablets to boost therapy effectiveness, augment patient adherence, and extend symptom control. These tablets gradually release medication over time, offering steady symptom control all day with just one dosage, thereby decreasing the need for more frequent doses. This improves convenience and treatment plan compliance for people dealing with ADHD. For example, JAMP Pharma Group, a Canadian pharmaceutical firm, introduced Guanfacine XR, a generic version of Takeda Canada Inc.’s INTUNIV XR—a branded drug for treating ADHD—in February 2022. Guanfacine XR is a long-lasting version of guanfacine that enhances attention, impulse control, and hyperactivity by influencing specific receptors in the brain. The drug comes in a 100-count bottle with various strengths (1 mg, 2 mg, 3 mg, and 4 mg), ensuring treatment flexibility.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21108
What regions are contributing significantly to the growth of the attention deficit hyperactivity disorder market?
North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Neurotrophic Keratitis Treatment Global Market Report 2025
Anorectal Disorders Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anorectal-disorders-treatment-global-market-report
Muscle Relaxant Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
